Randomized phase II trial evaluating the optimal sequencing of PD-1 inhibition with Pembrolizumab (MK-3475) and standard platinu

Skip to Content

Clinical Trial Details

Optimal Sequencing of Pembrolizumab and Standard Platinum-Based Chemotherapy in First-Line NSCLC

Randomized phase II trial evaluating the optimal sequencing of PD-1 inhibition with Pembrolizumab (MK-3475) and standard platinum-based chemotherapy in patients with chemotherapy naive stage IV non-small cell lung cancer.

Objective

Visit the National Cancer Institute's Web Site.

IRB Protocol Number
AFT-O9 NCT#02591615

Clinical Trial Categories

  • Lung Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000